InfuSystem (NYSEAMERICAN:INFU) Raised to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of InfuSystem (NYSEAMERICAN:INFU) from a strong sell rating to a hold rating in a research report report published on Wednesday, Zacks.com reports.

According to Zacks, “InfuSystem is a rapidly growing healthcare services company that provides state-of-the-art electronic continuous ambulatory infusion pumps, supplies and support to oncology practices and clinics throughout the United States. More than 60% of oncologists across all 50 states turn to InfuSystem as their single, full-service source for cost-effective infusion pump management. “

Separately, Northland Securities reissued a buy rating and issued a $27.00 price target on shares of InfuSystem in a research report on Wednesday, June 30th.

InfuSystem stock opened at $12.75 on Wednesday. InfuSystem has a fifty-two week low of $12.12 and a fifty-two week high of $23.26. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.37 and a quick ratio of 1.13. The company has a market capitalization of $262.24 million, a P/E ratio of 18.21 and a beta of 0.88.

InfuSystem (NYSEAMERICAN:INFU) last posted its earnings results on Thursday, August 12th. The medical instruments supplier reported $0.04 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.11 by ($0.07). InfuSystem had a net margin of 15.22% and a return on equity of 38.26%. The company had revenue of $24.83 million during the quarter, compared to analyst estimates of $27.50 million. On average, sell-side analysts expect that InfuSystem will post 0.17 EPS for the current year.

A number of hedge funds have recently modified their holdings of INFU. Legal & General Group Plc lifted its position in shares of InfuSystem by 48.5% during the 2nd quarter. Legal & General Group Plc now owns 2,453 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 801 shares during the last quarter. Perritt Capital Management Inc. lifted its position in shares of InfuSystem by 3.2% during the 1st quarter. Perritt Capital Management Inc. now owns 32,500 shares of the medical instruments supplier’s stock worth $662,000 after purchasing an additional 1,000 shares during the last quarter. Spouting Rock Asset Management LLC lifted its position in shares of InfuSystem by 7.2% during the 2nd quarter. Spouting Rock Asset Management LLC now owns 16,289 shares of the medical instruments supplier’s stock worth $339,000 after purchasing an additional 1,101 shares during the last quarter. Deutsche Bank AG lifted its position in shares of InfuSystem by 12.8% during the 2nd quarter. Deutsche Bank AG now owns 11,361 shares of the medical instruments supplier’s stock worth $236,000 after purchasing an additional 1,291 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC lifted its position in shares of InfuSystem by 28.0% during the 2nd quarter. O Shaughnessy Asset Management LLC now owns 7,874 shares of the medical instruments supplier’s stock worth $164,000 after purchasing an additional 1,723 shares during the last quarter. 62.26% of the stock is owned by institutional investors.

About InfuSystem

InfuSystem Holdings, Inc engages in the provision of health care services. It operates through the Integrated Therapy Services; and Durable Medical Equipment segments. The Integrated Therapy Services segment focuses on oncology such as providing ambulatory pumps to oncology offices, infusion clinics and hospital, and outpatient chemotherapy clinics.

Further Reading: Trading Strategy

Get a free copy of the Zacks research report on InfuSystem (INFU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.